PDCD1 and neoplasm: The strong correlation between ORAOV1 and aggressive tumor features, immunosuppressive TME, and poor response to anti-CTLA4/PD-1 therapy positions ORAOV1 as a dual-function biomarker suitable for prognostic stratification and treatment response prediction.